Real-world (RW) study of metastatic colorectal cancer (mCRC) patients (pts) with long-term response (LTR) to regorafenib (REG) in the USA: An updated analysis

被引：0
|
作者：
Kim, R. D. [1 ]
Pan, X. [2 ]
Zhang, Y. [2 ]
Lunacsek, O. [2 ]
Pisa, F. [3 ]
Ostojic, H. [4 ]
Peeters, M. [5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA
[2] Bayer Healthcare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ 07981 USA
[3] Bayer AG, Real World Evidence Oncol, Berlin, Germany
[4] Bayer Consumer Care AG, Real World Evidence Oncol, Basel, Switzerland
[5] Univ Hosp Antwerp, Ctr Oncol Res, Edegem, Belgium
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
83P
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [41] Regorafenib Combined With PD-1 Inhibition as Salvage Treatment and in a Real-World Study of Patients with Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 7 - 7
  • [42] Regorafenib monotherapy as the later-line treatment for elderly patients with metastatic colorectal cancer: a multicenter real-world study
    Huang, Jinglong
    Gong, Caifeng
    Jiang, Zhichao
    Qu, Wang
    Sun, Yongkun
    Teo, Nan Zun
    Zhang, Wen
    Yang, Lin
    Zhao, Yunbo
    Zhou, Aiping
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (05)
  • [43] Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).
    Khan, Khururn Hayat
    Rata, Mihaela
    Koh, Dow-Mu
    Tunariu, Nina
    Vlachogiannis, George
    Hahne, Jens
    Jamin, Yann
    Collins, David J.
    Chau, Ian
    Rao, Sheela
    Watkins, David J.
    Starling, Naureen
    Kalaitzaki, Eleftheria
    Fotiadis, Nicos
    Begum, Ruwaida
    Temple, Eleanor
    Fassan, Matteo
    Braconi, Chiara
    Cunningham, David
    Valeri, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [44] Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
    Yeh, Kun-Huei
    Yang, Tsai-Sheng
    Hsu, Tzu-Chi
    Chen, William Tzu-Liang
    Chen, Hong-Hwa
    Teng, Hao-Wei
    Lin, Bo-Wen
    Kuan, Feng-Che
    Chiang, Feng-Fan
    Duann, Chi-Wei
    Li, Ying-Shiuan
    Lin, Meng-Ting
    Fiala-Buskies, Sabine
    Ducreux, Michel
    Wang, Jaw-Yuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (11) : 2023 - 2031
  • [45] Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.
    Ducreux, Michel
    Ohler, Leopold
    Scheithauer, Werner
    Metges, Jean-Philippe
    Dourthe, Louis-Marie
    De Groot, Jan Willem
    Thaler, Josef
    Yeh, Kun-Huei
    Lin, Jen-Kou
    Falcone, Alfredo
    Punt, Cornelis J. A.
    Kalinovsky, Jan
    Fiala-Buskies, Sabine
    Cervantes, Andres
    O'Connor, Juan Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data
    Bekaii-Saab, Tanios
    Khan, Nasreen
    Ostojic, Helene
    Jiao, XiaoLong
    Chen, Guifang
    Lin, Wenlong
    Bruno, Amanda
    BMC CANCER, 2024, 24 (01)
  • [47] Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
    Lenz, Heinz-Josef
    Van Cutsem, Eric
    Verma, Udit N.
    Saltzman, Marc
    Fuloria, Jyotsna
    Khojasteh, Ali
    Wiesenfeld, Martin
    Cihon, Frank
    Wagner, Andrea
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
    Kim, George P.
    Van Cutsem, Eric
    Lenz, Heinz-Josef
    Verma, Udit N.
    Saltzman, Marc
    Fuloria, Jyotsna
    Khojasteh, Ali
    Wiesenfeld, Martin
    Cihon, Frank
    Wagner, Andrea
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: A retrospective analysis using US claims data
    Bekaii-Saab, T.
    Khan, N.
    Ostojic, H.
    Jiao, X.
    Chen, G.
    Lin, W.
    Bruno, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S285 - S286
  • [50] Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Satoh, Taroh
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Nishida, Toshirou
    Yamazaki, Naoya
    Takikawa, Haiime
    Morimoto, Takashi
    Chosa, Masayuki
    Sunaya, Toshiyuki
    Hamada, Yoko
    Muro, Kei
    Sugihara, Kenichi
    ONCOLOGIST, 2019, 24 (07): : E450 - E457
12345